Oncology and Hematology

Episodes 97-112 of 137

• 

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  RestartResume

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  MinuteCE®

  Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer

  1.00 credit 10 episodes

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 credit 10 episodes

• 

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  RestartResume

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  MinuteCE®

  Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  RestartResume

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  MinuteCE®

  Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  RestartResume

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  MinuteCE®

  Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  RestartResume

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  MinuteCE®

  Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  RestartResume

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  MinuteCE®

  Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC

  1.00 program credit

  • 

    

    Luis Paz-Ares, MD, PhD

  • 

    

    Helena Yu, MD

  • 

    

    Matthew Gubens, MD, MS

  1.00 program credit

• 

  RestartResume

  Late-Stage Bispecifics and ADCs in DLBCL

  RestartResume

  Late-Stage Bispecifics and ADCs in DLBCL

  MinuteCE®

  Late-Stage Bispecifics and ADCs in DLBCL

  1.00 program credit

  • 

    

    Sarah Rutherford, MD

  • 

    

    John P. Leonard, MD

  1.00 program credit

• 

  RestartResume

  Patient Selection for ADCs in First-Line DLBCL

  RestartResume

  Patient Selection for ADCs in First-Line DLBCL

  MinuteCE®

  Patient Selection for ADCs in First-Line DLBCL

  1.00 program credit

  • 

    

    John P. Leonard, MD

  • 

    

    Sarah Rutherford, MD

  1.00 program credit

• 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  RestartResume

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  MinuteCE®

  First-Line Treatment of Adults with Classical Hodgkin Lymphoma 

  1.00 program credit

  • 

    

    Alex Herrera, MD

  • 

    

    Alison J. Moskowitz, MD

  1.00 program credit

• 

  RestartResume

  Application of Data from the ECHELON-1 Trial

  RestartResume

  Application of Data from the ECHELON-1 Trial

  MinuteCE®

  Application of Data from the ECHELON-1 Trial

  1.00 program credit

  • 

    

    Alison J. Moskowitz, MD

  • 

    

    Alex Herrera, MD

  1.00 program credit

• 

  RestartResume

  Antibody-Drug Conjugates in FL

  RestartResume

  Antibody-Drug Conjugates in FL

  MinuteCE®

  Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Matthew J. Matasar, MD

  • 

    

    Kami Maddocks, MD

  1.00 program credit

• 

  RestartResume

  NCCN Guideline Updates in DLBCL

  RestartResume

  NCCN Guideline Updates in DLBCL

  MinuteCE®

  NCCN Guideline Updates in DLBCL

  1.00 program credit

  • 

    

    John P. Leonard, MD

  • 

    

    Sarah Rutherford, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  RestartResume

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  MinuteCE®

  Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

  • 

    

    Matthew J. Matasar, MD

  1.00 program credit

• 

  RestartResume

  Bispecific Antibodies in FL

  RestartResume

  Bispecific Antibodies in FL

  MinuteCE®

  Bispecific Antibodies in FL

  1.00 program credit

  • 

    

    Kami Maddocks, MD

  • 

    

    Matthew J. Matasar, MD

  1.00 program credit

• 

  RestartResume

  Individualizing Frontline Treatment

  RestartResume

  Individualizing Frontline Treatment

  MinuteCE®

  Individualizing Frontline Treatment

  1.00 program credit

  • 

    

    Alex Herrera, MD

  • 

    

    Alison J. Moskowitz, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 5
• 6
• 7
• 8
• 9
• Next